此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

检查 Testagen® TDS-睾酮 5% 的剂量范围研究 (PARC-T-D)

2026年9月29日 更新者:Transdermal Delivery Solutions Corp

在成年男性受试者中检测 Testagen® TDS-睾酮 5% 的多剂量、单周期、II 期剂量范围研究

This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.

研究概览

详细说明

48 Patients will be enrolled following 2 independent verifying blood tests of their diagnosis of Hypogonadism. there will be 4 cohorts of 12 subjects, each receiving doses of the trail materials, titrated by means of number of sprays applied. Doses will range from 10 to 70 mgs Testosterone.

研究类型

介入性

注册 (估计的)

48

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Chandan AS Alam, MD
  • 电话号码:011-44-7785-717596
  • 邮箱:calam@tdsc.us

学习地点

      • London、英国、NW1 4LJ
        • Advanced Therapies Centre, The London Clinic

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  1. Hypogonadal Male subjects - morning testosterone level ≤300 ng/dL (10.4 ng/L).
  2. 18 and 75 years of age, inclusive.
  3. The subject is willing and able to read, understand the Subject Information Sheet and provide written informed consent.
  4. The subject has a body mass index (BMI) within 18-30 kg/m2.
  5. The subject is in otherwise good health as determined by medical history and physical examination.
  6. The subject is a non-smoker.
  7. The subject must agree to comply with the placement of an indwelling catheter on two separate occasions and the drawing of blood samples for the pharmacokinetic assessments.
  8. The subject is willing and able to comply with all testing and requirements defined in the protocol.
  9. The subject is willing and able to return to the study site for all visits.

Exclusion Criteria:

  1. The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator, particularly an elevated PSA reading >4.0 ng/ml or ALT and AST greater than 2 times the upper limit of normal, clinically significant anemia (hematocrit <35%) or renal dysfunction (creatinine >2mg/dL), active deep vein thrombosis, thromboembolic disorders or history of these conditions.
  2. The subject has had a clinically significant illness within 30 days preceding entry into this study.
  3. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
  4. The subject has a known allergy or history of hypersensitivity to Testosterone or similar compounds.
  5. The subject has used any prescription medication within 14 days or over-the-counter (OTC) medication or alcohol within 48 hours of dosing or intends to use any prescription or OTC medication during the study that may interfere with the evaluation of study medication.
  6. The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and their haemoglobin concentration and haematocrit have not returned to within 5% of normal.
  7. The subject has a Hematocrit level > 51%
  8. The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
  9. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
  10. Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry.
  11. Subjects with an American Urological Association System Index for Prostatism score greater than 7
  12. Subjects with a history of prostate or breast carcinoma.
  13. Subjects with prostatic mass on screening physical examination.
  14. Subjects with a history of significant skin disease.
  15. Subjects with a history of sleep apnea.
  16. Subject with a partner with a history of breast cancer.
  17. Subject with a partner of child bearing potential who is not willing to use adequate contraception for the duration of the trial.
  18. Subject whose partner is pregnant.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Forearm dose

Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.

10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

A dose of product solution is delivered by means of a metered pump spray.

有源比较器:Chest Dose

Half of Ss will receive their dose of Testosterone on the chest.

10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

A dose of product solution is delivered by means of a metered pump spray.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Dose Range Measure of serum levels of testosterone in response to varying doses
大体时间:1 week

A pharmacokinetic measure of serum levels of testosterone in response to varying doses of from 10 to 70 mgs of Testosterone.

1 week

次要结果测量

结果测量
措施说明
大体时间
Dermal Safety as measured by
大体时间:1 Week

Incidence of treatment-emergent side effects.

1 Week

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Shern L. Chew, M.D., Ph.D.、Consultant Physician and Professor of Endocrine Medicine

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年6月1日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2028年2月1日

研究注册日期

首次提交

2013年7月3日

首先提交符合 QC 标准的

2013年7月9日

首次发布 (估计的)

2013年7月10日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2025年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • PARC-Testosterone-D1/09/13
  • 2013-001766-42 (EudraCT编号)
  • IRAS project ID: 146877 (其他标识符:NHS London - West London & GTAC Research Ethics Committee)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅